Xarelto
Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues
Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis
Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer
An estimated 84,870 people will be diagnosed with bladder cancer in the US this year
Bayer’s Kerendia granted FDA approval for new heart failure indication
Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours
The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway
J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients
Approximately 25% of cases are diagnosed during childhood or adolescence
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Inflammatory bowel disease is estimated to affect nearly two million people across Europe
J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer
The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC
Johnson & Johnson to invest more than $55bn in US over next four years
The commitment marks a 25% increase to the company's US investments in the past four years
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
An estimated three million people in the US are affected by inflammatory bowel disease
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme
More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease